# Using Positron Emission Tomography to Evaluate the Effects of Bevacizumab on Intra-tumoral Pharmacokinetics of 5-fluorouracil in Metastatic Colorectal Cancer

> **NCT00165568** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 20 (—)

## Conditions studied

- Colorectal Cancer
- Neoplasm Metastasis

## Interventions

- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00165568
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** —
- **Final completion:** 2006-10
- **Target enrollment:** 20 (—)
- **Last updated:** 2009-11-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00165568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00165568, "Using Positron Emission Tomography to Evaluate the Effects of Bevacizumab on Intra-tumoral Pharmacokinetics of 5-fluorouracil in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00165568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*